1-20 of 303
Jennifer R. Brown
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Clonal Evolution during Dual B Cell Receptor Pathway Inhibitor Therapy with Acalabrutinib and Umbralisib in CLL Patients

Saurabh Yadav, Sumbul Jawed Khan, Binu Kandathilparambil Sasi, Elizabeth F. Cohen, Kiyomi Mashima, Hannah Cormier, Stacey M. Fernandes, Samantha J. Shupe, Roberta Santos Azevedo, Mariia Mikhaleva, Philippe Armand, David C. Fisher, Matthew S. Davids, Inhye E. Ahn, Michael Y. Tolstorukov, Mark A. Murakami, Jennifer R. Brown
Journal: Blood
Blood (2024) 144 (Supplement 1): 4611.
https://doi.org/10.1182/blood-2024-207527
Published: 2024
Journal Articles

Characteristics and Outcomes of Patients with Double Refractory (DR) or Double Exposed (DE) CLL

James T. Yoon, Yinglu Zhou, Svitlana Tyekucheva, Mariia Mikhaleva, Stacey M. Fernandes, Philippe Armand, Amy C. Bessnow, Jennifer L. Crombie, David C. Fisher, Eric D. Jacobsen, Caron A. Jacobson, Austin I. Kim, Ann S. LaCasce, Reid W. Merryman, Oreofe O. Odejide, Erin M. Parry, David A. Qualls, Christine E. Ryan, Aswin Sekar, Jacob D. Soumerai, Jon E. Arnason, Matthew S. Davids, Jennifer R. Brown, Inhye E. Ahn
Journal: Blood
Blood (2024) 144 (Supplement 1): 4617.
https://doi.org/10.1182/blood-2024-199577
Published: 2024
Journal Articles

A Phase 2 Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter's Syndrome (RS)

Jennifer L. Crombie, Christine E. Ryan, Yue Ren, Svitlana Tyekucheva, Celeste Carey, Aaron Zou, Samantha Normilus, Josie Montegaard, Jacob D. Soumerai, Shruti Bhandari, Jon E. Arnason, Alvaro J Alencar, Austin I. Kim, Erin M. Parry, Philippe Armand, David C. Fisher, Jennifer R. Brown, Matthew S. Davids
Journal: Blood
Blood (2024) 144 (Supplement 1): 4628.
https://doi.org/10.1182/blood-2024-199234
Published: 2024
Journal Articles

Treatment Outcomes of Patients Treated with Venetoclax-Obinutuzumab Therapy Vs Btki Therapies in 1L CLL: An International Real-World Study

Nicole Lamanna, Jennifer R. Brown, Chaitra S. Ujjani, Toby A. Eyre, Beenish Manzoor, Nilanjan Ghosh, Lindsey Roeker, Matthew S. Davids, Catherine C Coombs, Alan P Skarbnik, Brian T. Hill, Hande H. Tuncer, Lori A. Leslie, Joanna M. Rhodes, Isabelle Fleury, Paul M Barr, Nnadozie Emechebe, Nicolas Martinez-Calle, Christopher E. Jensen, Yun Choi, Dureshahwar Jawaid, Laurie K Pearson, Meghan C. Thompson, Steven E Marx, Wendy J. Sinai, Frederick Lansigan, Bita Fakhri, Deborah M. Stephens, Stephen J. Schuster, Michael Coyle, Irina Pivneva, Talissa Watson, Annie Guerin, Mazyar Shadman
Journal: Blood
Blood (2024) 144 (Supplement 1): 4625.
https://doi.org/10.1182/blood-2024-205223
Published: 2024
Journal Articles

Preliminary Efficacy and Safety of a Phase 1/2 Study of Acalabrutinib, Venetoclax, and Obinutuzumab in Patients with Relapsed/Refractory and Previously Untreated Mantle Cell Lymphoma (MAVO)

Austin I. Kim, Philippe Armand, Christine E. Ryan, Robert A. Redd, Megan Forsyth, Juniper Mai, Samantha Pazienza, Caitlin Bresnahan, Vanessa M Kats, Salah Abdulkarim, Susan M Waisgerber, Reid W. Merryman, David C. Fisher, Inhye E. Ahn, Jennifer L. Crombie, Oreofe O. Odejide, Ann S. LaCasce, Caron A. Jacobson, Eric D. Jacobsen, Erin M. Parry, David A. Qualls, Amy C. Bessnow, Matthew S. Davids, Jennifer R. Brown, Jon E. Arnason, Michael Leukam, Peter A. Riedell, Mark A. Murakami
Journal: Blood
Blood (2024) 144 (Supplement 1): 4408.
https://doi.org/10.1182/blood-2024-198056
Published: 2024
Journal Articles

Identifying Novel Drug Vulnerabilities in Specified Molecular Subsets of Chronic Lymphocytic Leukemia

Salma Parvin, Binyamin Knisbacher, Aditi Aryal, Stacey M. Fernandes, Shlomi Medalion, Guy Leib, Johan Gustafsson, Shir Amit, Eden C Meidan, Nadav Y Klein, Savion Nafussy, Donna S. Neuberg, Catherine J. Wu, Jennifer R. Brown, Gad Getz, Anthony G. Letai
Journal: Blood
Blood (2024) 144 (Supplement 1): 76.
https://doi.org/10.1182/blood-2024-201594
Published: 2024
Journal Articles

Outcomes of Therapies Following Discontinuation of Non-Covalent Bruton's Tyrosine Kinase Inhibitors for Patients with Chronic Lymphocytic Leukemia and Richter Transformation: Results from an International, Multicenter Study

Meghan C. Thompson, Seema A. Bhat, Wojciech Jurczak, Krish Patel, Nirav N. Shah, Jennifer A. Woyach, Catherine C. Coombs, Toby A. Eyre, Michal Danecki, Monika Dlugosz-Danecka, Neil Bailey, Joanna M. Rhodes, Nicole Lamanna, Andrew H. Lipsky, Jeffrey Jensen, Adam Kidwell, Eytan M. Stein, Monica Shah, Jennifer R. Brown, Andriy Derkach, Anthony R. Mato, Lindsey Roeker
Journal: Blood
Blood (2024) 144 (Supplement 1): 1870.
https://doi.org/10.1182/blood-2024-194748
Published: 2024
Journal Articles

Primary Endpoint Evaluation of a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease

Matthew S. Davids, Christine E. Ryan, Yue Ren, Liam Hackett, Jeremy Zhang, Svitlana Tyekucheva, Stacey M. Fernandes, Jennifer L. Crombie, Austin I. Kim, Matthew Weinstock, Josie Montegaard, Heather A. Walker, Claire Greenman, Victoria Patterson, Caron A. Jacobson, Ann S. LaCasce, Philippe Armand, David C. Fisher, Steve Lo, Adam J. Olszewski, Jon E. Arnason, Inhye E. Ahn, Jennifer R. Brown
Journal: Blood
Blood (2024) 144 (Supplement 1): 1865.
https://doi.org/10.1182/blood-2024-206556
Published: 2024
Journal Articles

The Impact of Therapeutic Selective Pressure on the Evolutionary Landscape of Chronic Lymphocytic Leukemia

Negin Karisani, Amit Sud, Liang Li, Satyen Gohil, Kristy Schlueter-Kuck, Laura Rassenti, Tuan N. Tran, Leo Wang-Kit Cheung, Iliana Edith Szafer-Glusman, James P. Dean, Guang Chen, Junko Tsuji, Neil E. Kay, Kanti R. Rai, Jennifer R. Brown, John G. Gribben, John C. Byrd, Donna S. Neuberg, Chip Stewart, Ivana Bozic, Thomas J. Kipps, Gad Getz, Catherine J. Wu
Journal: Blood
Blood (2024) 144 (Supplement 1): 3233.
https://doi.org/10.1182/blood-2024-199916
Published: 2024
Journal Articles

Low Variant Allele Frequency (VAF) TP53 Mutation (mut) Is Not a Poor Prognostic Marker in CLL Patients Treated with Targeted Therapy

Daniel Sungchul Choi, Yue Ren, Svitlana Tyekucheva, Stacey M. Fernandes, Mariia Mikhaleva, Kiyomi Mashima, Rayan Fardoun, Samantha J. Shupe, Stephen Martindale, Matthew S. Davids, Jennifer R. Brown, Inhye E. Ahn
Journal: Blood
Blood (2024) 144 (Supplement 1): 587.
https://doi.org/10.1182/blood-2024-208951
Published: 2024
Journal Articles

Ipilimumab with and without Nivolumab in Patients with Classic Hodgkin Lymphoma with Progression after PD-1 Blockade

Reid W. Merryman, Justin Kline, Robert A. Redd, Emma L. Welsh, Kathleen Pfaff, Hannah Juhaie Lee, Mikaela M. McDonough, Inhye E. Ahn, Jennifer R. Brown, Jennifer L. Crombie, Matthew S. Davids, David C. Fisher, Eric D. Jacobsen, Caron A. Jacobson, Austin I. Kim, Oreofe O. Odejide, Erin M. Parry, Christine E. Ryan, Margaret A. Shipp, Philippe Armand, Scott J. Rodig, Jeremy S. Abramson, Ann S. LaCasce
Journal: Blood
Blood (2024) 144 (Supplement 1): 1669.
https://doi.org/10.1182/blood-2024-203414
Published: 2024
Journal Articles

Complex Karyotype, but Not Isolated TP53 mutation, Predicts Overall Survival in Chronic Lymphocytic Leukemia Patients in the Era of Targeted Therapy

Roberta Santos Azevedo, Mariia Mikhaleva, Kiyomi Mashima, Stephen Martindale, Stacey M. Fernandes, Svitlana Tyekucheva, Inhye E. Ahn, Matthew S. Davids, Jennifer R. Brown
Journal: Blood
Blood (2024) 144 (Supplement 1): 583.
https://doi.org/10.1182/blood-2024-206576
Published: 2024
Journal Articles

Fixed-Duration Acalabrutinib Plus Venetoclax with or without Obinutuzumab Versus Chemoimmunotherapy for First-Line Treatment of Chronic Lymphocytic Leukemia: Interim Analysis of the Multicenter, Open-Label, Randomized, Phase 3 AMPLIFY Trial

Jennifer R. Brown, John F. Seymour, Wojciech Jurczak, Andrew Aw, Malgorzata Wach, Arpad Illes, Alessandra Tedeschi, Carolyn Owen, Alan P Skarbnik, Daniel Lysak, Ki-Seong Eom, Martin Šimkovič, Miguel Arturo Pavlovsky, Arnon P. Kater, Barbara F. Eichhorst, Kara Miller, Veerendra Munugalavadla, Ting Yu, Marianne de Borja, Paolo Ghia
Journal: Blood
Blood (2024) 144 (Supplement 1): 1009.
https://doi.org/10.1182/blood-2024-200701
Published: 2024
Journal Articles

Sustained Superiority of Zanubrutinib vs Bendamustine + Rituximab in Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (TN CLL): 5-Year Follow-Up of Cohort 1 from the SEQUOIA Study

Mazyar Shadman, Talha Munir, Tadeusz Robak, Jennifer R. Brown, Brad S. Kahl, Paolo Ghia, Tian Tian, Andy Szeto, Roman Korolkiewicz, Constantine S. Tam, Wojciech Jurczak
Journal: Blood
Blood (2024) 144 (Supplement 1): 3249.
https://doi.org/10.1182/blood-2024-194864
Published: 2024
Journal Articles

A Phase 2 Study of Zanubrutinib and Venetoclax (ZV) in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Inhye E. Ahn, Yue Ren, David C. Fisher, Austin I. Kim, Nancy E. Kaddis, Jon E. Arnason, John P. Winters, III, Sobana Balasubramanian, Heather A. Walker, Victoria Patterson, Stacey M. Fernandes, Svitlana Tyekucheva, Matthew S. Davids, Jennifer R. Brown
Journal: Blood
Blood (2024) 144 (Supplement 1): 1874.
https://doi.org/10.1182/blood-2024-201668
Published: 2024
Journal Articles

Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trial

Clinical Trials & Observations
Lindsey E. Roeker, Jennifer A. Woyach, Chan Y. Cheah, Catherine C. Coombs, Nirav N. Shah, William G. Wierda, Manish R. Patel, Nicole Lamanna, Donald E. Tsai, Binoj Nair, Chunxiao Wang, Xiang Zhao, Dan Liu, David Radtke, Sonya Chapman, Narasimha Marella, Samuel C. McNeely, Jennifer R. Brown
Journal: Blood
Blood (2024) 144 (13): 1374–1386.
https://doi.org/10.1182/blood.2024024510
Published: 2024
Includes: Supplemental data
Journal Articles

Sustained Benefit of Zanubrutinib vs Ibrutinib in Patients With R/R CLL/SLL: Final Comparative Analysis of ALPINE

Clinical Trials & Observations
Jennifer R. Brown, Barbara Eichhorst, Nicole Lamanna, Susan M O'Brien, M.D., Constantine S. Tam, Lugui Qiu, Wojciech Jurczak, Keshu Zhou, Martin Šimkovič, Jiří Mayer, Amanda Gillespie-Twardy, Alessandra Ferrajoli, Peter Stephen Ganly, Robert Weinkove, Sebastian Grosicki, Andrzej Mital, Tadeusz Robak, Prof., Anders Osterborg, Habte A. Yimer, Megan (Der Yu) Wang, Tommi Salmi, Liping Wang, Jessica Li, Kenneth Wu, Aileen Cleary Cohen, Mazyar Shadman
Journal: Blood
Blood blood.2024024667.
https://doi.org/10.1182/blood.2024024667
Published: 2024
Includes: Supplemental data
Journal Articles

Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL

CME Clinical Trials & Observations
Jennifer A. Woyach, Gabriela Perez Burbano, Amy S. Ruppert, Cecelia Miller, Nyla A. Heerema, Weiqiang Zhao, Anna Wall, Wei Ding, Nancy L. Bartlett, Danielle M. Brander, Paul M. Barr, Kerry A. Rogers, Sameer A. Parikh, Deborah M. Stephens, Jennifer R. Brown, Gerard Lozanski, James Blachly, Sreenivasa Nattam, Richard A. Larson, Harry Erba, Mark Litzow, Selina Luger, Carolyn Owen, Charles Kuzma, Jeremy S. Abramson, Richard F. Little, Shira Dinner, Richard M. Stone, Geoffrey Uy, Wendy Stock, Sumithra J. Mandrekar, John C. Byrd
Journal: Blood
Blood (2024) 143 (16): 1616–1627.
https://doi.org/10.1182/blood.2023021959
Published: 2024
Includes: Supplemental data
Journal Articles

Pirtobrutinib in Post-cBTKi CLL/SLL: ~30 Months Follow-up and Subgroup Analysis With/Without Prior BCL2i from the Phase 1/2 BRUIN Study

Jennifer A. Woyach, Jennifer R. Brown, Paolo Ghia, Lindsey E. Roeker, Krish Patel, Toby A. Eyre, Talha Munir, Ewa Lech-Maranda, Nicole Lamanna, Constantine S. Tam, John F. Seymour, Benoit Tessoulin, Nirav N. Shah, Chaitra S Ujjani, Bita Fakhri, Catherine C. Coombs, Ian W. Flinn, Manish Patel, Sunita D. Nasta, Jonathon B. Cohen, Alvaro J. Alencar, Chan Y. Cheah, Shuo Ma, Joanna M. Rhodes, Deepa Jagadeesh, Pier Luigi Zinzani, Anders Osterborg, Koji Izutsu, Donald E. Tsai, Paolo Abada, Minna Balbas, Jian Li, Amy S. Ruppert, Wojciech Jurczak, William G. Wierda
Journal: Blood
Blood (2023) 142 (Supplement 1): 325.
https://doi.org/10.1182/blood-2023-185852
Published: 2023
Journal Articles

Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Marginal Zone Lymphoma: Results from Phase 1/2 BRUIN Study

Krish Patel, Julie M. Vose, Sunita D. Nasta, Jennifer R. Brown, Kami J. Maddocks, Jennifer A. Woyach, Nirav N. Shah, Bita Fakhri, Benoit Tessoulin, Shuo Ma, Deepa Jagadeesh, Ewa Lech-Maranda, Catherine C. Coombs, Manish Patel, Joanna M. Rhodes, Chaitra S Ujjani, Marc S. Hoffmann, Chan Y Cheah, Talha Munir, David Lewis, Lydia Scarfo, Toby A. Eyre, Alvaro J. Alencar, Jonathon B. Cohen, Andrew D. Zelenetz, Donald E. Tsai, Mei Li, Faith Bian, Paolo Abada, Pier Luigi Zinzani
Journal: Blood
Blood (2023) 142 (Supplement 1): 1660.
https://doi.org/10.1182/blood-2023-180048
Published: 2023